7B.03: SAFETY OF BETA-AGONISTS WITH DIFFERENT DURATION OF ACTION IN PATIENTS WITH ARTERIAL HYPERTENSION AND BRONCHO-OBSTRUCTIVE DISEASES. (June 2015)

• Record Type: Journal Article
• Authors: Dolgusheva, I.; Agapova, O.; Zykov, K.; Sivacova, O.; Golitsyn, P.; Chazova, I.
• Is Part Of: Journal of hypertension. Volume 33(2015)Supplement 1
• Publication Date: 2015-06
• Subjects: Hypertension -- Periodicals; Hypertension -- Periodicals; 616.132005
• DOI: 10.1097/01.hjh.0000467600.09175.5a
• Languages: English
• ISSNs: 1473-5598

Abstract

Abstract : Objective: To evaluate the safety of beta-agonists (BA) with different duration of action (short-acting (SABA), long-acting (LABA), ultra-long-acting (ULABA) in patients with arterial hypertension (AH) and chronic obstructive pulmonary disease (COPD) or bronchial asthma. Design and method: 40 patients with AH and COPD (gr.1) and AH and asthma (gr.2) were enrolled and examined initially. At the next three month patients were treated with 3 types of BA: at the 1st month – with salbutamol (SABA), at 2nd month –with formoterol (LABA), at 3rd month –with indacaterol (ULABA). Initially, after one week and at the end of each month blood pressure (BP) and heart rate (HR) on the visit, serum potassium in blood, electrocardiogram, were evaluate. After one week and at the end of three month of treatment with BA all patients underwent Holter monitoring and ambulatory blood pressure 24-monitoring (ABPM). Results are presented as Mean ± sd. Results: Patients were 64 ± 7, 7years (22-male, 18-female), with BMI 29, 8 ± 5, 3 kg/m2; BP in gr.1 was 128, 4 ± 14, 3/81, 1 ± 19, 7 and 135 ± 13/83 ± 9, 9 mmHg in gr.2, p = NS, initially. Baseline, 1-month, 2-month, 3-month BP and HR levels on the visit were similar among all patients (p = NS). At the end of the third month of treatment with BA different duration of action in gr.1 daily average Systolic BP (SBP) was lowered than initially (129 ± 10, 2 vs 124 ± 10, 5, p < 0, 05). On the contrary in gr.2 daily average SBP became increased than initially (122 ± 14, 1 vs 127 ± 16, p < 0, 05). Treatment with BA caused significant serum potassium change in blood in both group: in gr.1 initially was 4, 5 ± 0, 5 mmol/l, after SABA use - 4, 2 ± 0, 4(p < 0, 05), LABA- 4, 1 ± 0, 4(p = NS), ULABA-4, 2 ± 0, 4(p < 0, 05); in gr.2 initially was 4, 4 ± 0, 4 mmol/l, after use SABA- 4, 1 ± 0, 3(p < 0, 05), LABA- 4, 3 ± 0, 3(p = NS), ULABA-4, 15 ± 0, 6(p < 0, 05). In gr.2. three patients had hypokalemia. Conclusions: Treatment with BA in patients with AH and bronchoobstructive diseases significantly decreased levels of serum potassium in the blood in both group and led to reduction of daily average SBP and in contrast treatment of patients with AH and asthma resulted in increasing of daily average SBP. Our results suggested the need for a different treatment of patients with AH and COPD or asthma.